Supporting your choice of surgical therapies for your patients with coronary artery disease (CAD).
Hybrid Coronary Revascularization (HCR) is a treatment plan that combines MICS CABG and Percutaneous Coronary Intervention (PCI). Partnering in either a staged or simultaneous approach, the cardiac surgeon performs the LIMA to LAD anastomosis (MICS CABG) and the interventional cardiologist stents the non-LAD territories. The procedure can be performed as a:
HCR may be an option for patients who ask for a less invasive cardiac therapy. It combines the durability of coronary artery bypass surgery (CABG with LIMA) to the critical LAD territory with the minimal invasiveness of PCI to non-LAD targets. Its advantages include:
The many benefits to clinicians who work together as a heart team to perform HCR, include:
Many patients may benefit from HCR. Consider the following criteria when deciding if your patients are eligible for the procedure.
Good Candidates for HCR4
More than 20 years ago, when we introduced the Octopus™ tissue stabilizers for OPCAB, it changed the way cardiac surgeons could perform beating heart surgeries. For the first time, epicardial tissue could be stabilized using vacuum-assisted technology to complete anastomoses. Today, tissue stabilizers are seen as standard for beating heart therapies. The Octopus Nuvo tissue stabilizer, Starfish™ NS heart positioner, and ThoraTrak™ MICS retractor system are the technologies available from Medtronic to help you perform your HCR procedures.
Hybrid Coronary Revascularization (HCR) procedures are becoming more mainstream today. As the patient population changes, so do the demands on you, the cardiac surgeon. That’s why Medtronic is committed to supporting HCR. Together — with your skilled knowledge and our enabling technologies — we can deliver the right therapies for each individual patient with coronary artery disease (CAD).
Learn new beating heart skills and gain hands-on experience with technologies that may be new to you. We offer a full range of training programs. Contact us to learn more.
Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1985; Jan 2;Vol. 314 (1), pp.1-6.
Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. New Eng J Med. 2009;360:961-972.
Poston RS, Trans R, Collins M, et al. Comparison of economic and patient outcomes with minimally invasive versus traditional off-pump coronary artery bypass grafting techniques. Ann Surg. 2008;248:638-646.
Kiaii B, Teefy P, Sridhar K, Chu M. London Health Sciences Centre Hybrid Coronary Revascularization Technique Guide. April 2014.
Not all patients are candidates for beating heart procedures. Some patients would require cardiopulmonary support during surgery. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. For a listing of indications, contraindications, precautions and warnings, please refer to the Instructions for Use.